Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19751645 | 0.77 | MAOA (0.52) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL14395012 | 0.75 | MAOA (0.50) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL9321525 | 0.75 | MAOA (0.50) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL5241115 | 0.75 | MTNR1A (0.47) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL703737 | 0.75 | MAOA (0.50) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL11841854 | 0.73 | MAOA (0.48) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL10783453 | 0.73 | MAOA (0.44) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL9145493 | 0.73 | MAOA (0.44) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL6822134 | 0.70 | ALDH1A1 (0.44) | MAOARNASEH1CES1BCHEALDH1A1 | |
| SCHEMBL11788999 | 0.69 | MAOA (0.48) | MAOARNASEH1CES1BCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368017-A1 | ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-05-14 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-15 | — | — | US | disclosed |
| EP-1214311-B1 | NOVEL INDENO-FUSED PHOTOCHROMIC NAPHTHOPYRANS | TRANSITIONS OPTICAL INC (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1214311-A1 | NOVEL INDENO-FUSED PHOTOCHROMIC NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6296785-B1 | OPHTHALMIC AND CONTACT LENSES; WINDOWS, SAFETY GLASS FOR CARS | PPG INDUSTRIES OHIO, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001019813-A1 | NOVEL INDENO-FUSED PHOTOCHROMIC NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | BACE1, PSEN1, APP | MAOA 1885/4885RNASEH1 2617/4885CES1 125/4885 |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | BACE1, PSEN1, APP | MAOA 1885/4885RNASEH1 2617/4885CES1 125/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | MAOA 2843/4885RNASEH1 2621/4885CES1 3717/4885 |
| US-20170368017-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | MAOA 3061/4885RNASEH1 1839/4885CES1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.